Product Comparison

Comparison Options

• Print
• Email
• Export Compare

		No Image
McKesson #	1184514	1104090	1146499	1148266	709324
Description	Benlysta® Belimumab 120 mg Injection 5 mL	Sirolimus 1 mg Tablet 100 Tablets	Tacrolimus 5 mg Capsule 100 Capsules	Mycophenolate Mofetil 500 mg Capsule 100 Capsules	Mycophenolate Mofetil 500 mg Tablet 100 Tablets
Manufacturer #	49401010101	55111065301	00378204701	64380072506	00054016625
Brand	Benlysta®
Manufacturer	Glaxo Specialty (Medical Benefit)	Dr. Reddy's Laboratories	Mylan Pharmaceuticals	Strides Pharma	Hikma Pharmaceuticals USA
Invoice	BENLYSTA, VL 120MG/5ML	SIROLIMUS, TAB 1MG (100/BT) 1 MG	TACROLIMUS, CAP 5MG (100/BT)	MYCOPHENOLATE MOFETIL, CAP 500MG (100/BT)	MYCOPHENOLATE, TAB 500MG (100/BT)
	Log In to Order	Log In to Order	Log In to Order	Log In to Order	Log In to Order
Comparison
Alternate Manufacturer Number		3295573	1155332	3226099	2534873
Container Type	Single-Use Vial	Bottle	Bottle	Bottle	Bottle
Dosage Form	Injection	Tablet	Capsule	Capsule	Tablet
Generic Drug Code		13696	28492	47561	47561
Generic Drug Name	Belimumab	Sirolimus	Tacrolimus	Mycophenolate Mofetil	Mycophenolate Mofetil
NDC Number	49401010101	55111065301	00378204701	64380072506	00054016625
Product Dating	McKesson Acceptable Dating: we will ship >= 180 days	McKesson Acceptable Dating: we will ship >= 90 days	McKesson Acceptable Dating: we will ship >= 90 days	McKesson Acceptable Dating: we will ship >= 90 days	McKesson Acceptable Dating: we will ship >= 90 days
Quantity		100 Tablets	100 Capsules	100 Capsules	100 Tablets
Storage Requirements	Requires Refrigeration
Strength	120 mg	1 mg	5 mg	500 mg	500 mg
Type	Intravenous
UNSPSC Code	51202403	51202803	51202804	51203201	51203201
Volume	5 mL
Application	Immunosuppressive Agent	Immunosuppressive Agent	Immunosuppressive Agent	Immunosuppressive Agent	Immunosuppressive Agent
Country of Origin	Unknown	Unknown	Unknown	Unknown	Unknown
Features and Benefits	BENLYSTA is a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of: patients aged 5 years and older with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy BENLYSTA is a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of: adult patients with active lupus nephritis who are receiving standard therapy. BENLYSTA (belimumab) for injection is a sterile, preservative-free, lyophilized powder for reconstitution and dilution prior to intravenous infusion provided in single‑dose glass vials with a rubber stopper (not made with natural rubber latex) and a flip‑off seal. Each 5‑mL vial contains 120 mg of belimumab. Requires Refrigeration	WARNING: Cancer and Reproductive Harm - www.P65Warnings.ca.gov			Immunosuppressant drug used to prevent rejection in organ transplantation